| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Smoking | 60 | 2022 | 1449 | 6.740 |
Why?
|
| Skin Neoplasms | 19 | 2020 | 375 | 5.890 |
Why?
|
| Ovarian Neoplasms | 34 | 2022 | 267 | 4.510 |
Why?
|
| Smoking Cessation | 27 | 2022 | 1032 | 3.850 |
Why?
|
| Lung Neoplasms | 29 | 2020 | 1172 | 3.490 |
Why?
|
| Neoplasms | 19 | 2022 | 1664 | 3.270 |
Why?
|
| Neoplasms, Second Primary | 8 | 2019 | 61 | 2.850 |
Why?
|
| Carcinoma, Basal Cell | 9 | 2019 | 40 | 2.540 |
Why?
|
| Risk Factors | 90 | 2020 | 5720 | 2.340 |
Why?
|
| Tobacco Smoke Pollution | 12 | 2014 | 127 | 2.050 |
Why?
|
| Case-Control Studies | 66 | 2021 | 1549 | 2.010 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2019 | 624 | 2.000 |
Why?
|
| Humans | 216 | 2022 | 68549 | 1.880 |
Why?
|
| Female | 162 | 2022 | 38021 | 1.820 |
Why?
|
| Middle Aged | 129 | 2020 | 21119 | 1.780 |
Why?
|
| Keratinocytes | 3 | 2019 | 68 | 1.760 |
Why?
|
| Nicotine | 10 | 2022 | 350 | 1.730 |
Why?
|
| Medical Oncology | 5 | 2022 | 110 | 1.710 |
Why?
|
| Head and Neck Neoplasms | 14 | 2021 | 561 | 1.610 |
Why?
|
| Aged | 103 | 2020 | 14842 | 1.560 |
Why?
|
| Tobacco Products | 5 | 2022 | 234 | 1.500 |
Why?
|
| Adult | 101 | 2022 | 21379 | 1.440 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2022 | 627 | 1.410 |
Why?
|
| Male | 108 | 2022 | 37283 | 1.400 |
Why?
|
| DNA Repair | 5 | 2012 | 127 | 1.300 |
Why?
|
| Maryland | 26 | 2013 | 77 | 1.170 |
Why?
|
| Breast Neoplasms | 22 | 2020 | 1533 | 1.120 |
Why?
|
| Diet | 10 | 2021 | 514 | 1.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 848 | 1.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2017 | 766 | 1.090 |
Why?
|
| Odds Ratio | 28 | 2019 | 880 | 1.080 |
Why?
|
| United States | 44 | 2022 | 7338 | 1.020 |
Why?
|
| Vegetables | 4 | 2010 | 76 | 1.020 |
Why?
|
| Electronic Nicotine Delivery Systems | 3 | 2022 | 180 | 0.990 |
Why?
|
| Attitude to Health | 7 | 2019 | 403 | 0.990 |
Why?
|
| Risk Assessment | 17 | 2019 | 2004 | 0.980 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2012 | 300 | 0.930 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2010 | 138 | 0.920 |
Why?
|
| Carcinoma | 4 | 2016 | 215 | 0.910 |
Why?
|
| Cohort Studies | 21 | 2022 | 2356 | 0.890 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2017 | 285 | 0.870 |
Why?
|
| Smoking Prevention | 8 | 2014 | 259 | 0.860 |
Why?
|
| Prospective Studies | 29 | 2021 | 3703 | 0.860 |
Why?
|
| Receptors, Nicotinic | 1 | 2022 | 41 | 0.840 |
Why?
|
| Neoplasms, Glandular and Epithelial | 6 | 2017 | 22 | 0.830 |
Why?
|
| Health Status Disparities | 6 | 2016 | 326 | 0.830 |
Why?
|
| Tobacco, Smokeless | 3 | 2017 | 40 | 0.820 |
Why?
|
| Colorectal Neoplasms | 4 | 2018 | 560 | 0.820 |
Why?
|
| Incidence | 20 | 2018 | 1582 | 0.810 |
Why?
|
| Motivation | 6 | 2019 | 561 | 0.800 |
Why?
|
| South Carolina | 15 | 2019 | 2752 | 0.800 |
Why?
|
| Carotenoids | 8 | 2015 | 45 | 0.770 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2019 | 786 | 0.770 |
Why?
|
| Smokers | 4 | 2022 | 198 | 0.760 |
Why?
|
| Biomarkers, Tumor | 7 | 2019 | 508 | 0.760 |
Why?
|
| Social Support | 4 | 2018 | 423 | 0.750 |
Why?
|
| Melanoma | 4 | 2011 | 335 | 0.740 |
Why?
|
| Patient Navigation | 2 | 2020 | 30 | 0.740 |
Why?
|
| Environmental Exposure | 6 | 2013 | 269 | 0.710 |
Why?
|
| Socioeconomic Factors | 13 | 2016 | 955 | 0.690 |
Why?
|
| Health Surveys | 6 | 2019 | 488 | 0.690 |
Why?
|
| Nicotinic Agonists | 3 | 2011 | 111 | 0.690 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2012 | 207 | 0.690 |
Why?
|
| Papillomaviridae | 4 | 2016 | 87 | 0.670 |
Why?
|
| Proportional Hazards Models | 13 | 2020 | 791 | 0.670 |
Why?
|
| Exercise Therapy | 2 | 2011 | 183 | 0.660 |
Why?
|
| Papillomavirus Vaccines | 2 | 2017 | 82 | 0.650 |
Why?
|
| Patient Participation | 1 | 2020 | 145 | 0.640 |
Why?
|
| Survivors | 2 | 2011 | 254 | 0.640 |
Why?
|
| Colonic Neoplasms | 3 | 2015 | 299 | 0.630 |
Why?
|
| Papillomavirus Infections | 5 | 2017 | 163 | 0.630 |
Why?
|
| Minority Groups | 1 | 2020 | 196 | 0.630 |
Why?
|
| Aged, 80 and over | 28 | 2019 | 4843 | 0.620 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2009 | 10 | 0.620 |
Why?
|
| Social Class | 2 | 2016 | 127 | 0.610 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2016 | 46 | 0.610 |
Why?
|
| Bupropion | 2 | 2022 | 63 | 0.600 |
Why?
|
| Follow-Up Studies | 15 | 2020 | 3256 | 0.600 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2014 | 79 | 0.580 |
Why?
|
| Receptors, Calcitriol | 2 | 2019 | 49 | 0.580 |
Why?
|
| Air Pollution, Indoor | 2 | 2008 | 26 | 0.580 |
Why?
|
| Caregivers | 2 | 2018 | 365 | 0.580 |
Why?
|
| Prevalence | 9 | 2020 | 1609 | 0.570 |
Why?
|
| Polymorphism, Genetic | 7 | 2012 | 301 | 0.570 |
Why?
|
| Water Pollutants, Chemical | 2 | 2013 | 328 | 0.560 |
Why?
|
| Tobacco Use | 2 | 2015 | 98 | 0.560 |
Why?
|
| DNA Helicases | 3 | 2012 | 64 | 0.560 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2017 | 467 | 0.550 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 18 | 0.530 |
Why?
|
| Surveys and Questionnaires | 20 | 2021 | 2798 | 0.520 |
Why?
|
| Genotype | 10 | 2022 | 785 | 0.520 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 209 | 0.520 |
Why?
|
| Vitamin D | 5 | 2019 | 516 | 0.510 |
Why?
|
| Poverty | 2 | 2018 | 218 | 0.510 |
Why?
|
| Self Disclosure | 1 | 2015 | 55 | 0.510 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 2265 | 0.510 |
Why?
|
| Pediatrics | 2 | 2018 | 341 | 0.510 |
Why?
|
| Young Adult | 20 | 2019 | 5710 | 0.510 |
Why?
|
| Colonic Polyps | 1 | 2015 | 63 | 0.510 |
Why?
|
| Body Mass Index | 9 | 2020 | 866 | 0.510 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.500 |
Why?
|
| Ultraviolet Rays | 2 | 2016 | 130 | 0.490 |
Why?
|
| Policy | 3 | 2022 | 58 | 0.480 |
Why?
|
| Adolescent | 24 | 2022 | 8904 | 0.480 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2019 | 14 | 0.480 |
Why?
|
| Carcinogens | 3 | 2010 | 86 | 0.480 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.480 |
Why?
|
| Vaping | 3 | 2022 | 124 | 0.470 |
Why?
|
| Prognosis | 17 | 2019 | 2093 | 0.460 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2013 | 2 | 0.450 |
Why?
|
| Arsenic Poisoning | 1 | 2013 | 5 | 0.450 |
Why?
|
| Tobacco | 2 | 2016 | 161 | 0.450 |
Why?
|
| Public Health Administration | 1 | 2013 | 36 | 0.440 |
Why?
|
| Dehydroepiandrosterone | 4 | 2001 | 29 | 0.440 |
Why?
|
| Counseling | 3 | 2020 | 279 | 0.440 |
Why?
|
| Tobacco Use Disorder | 4 | 2017 | 432 | 0.430 |
Why?
|
| Telephone | 3 | 2014 | 160 | 0.430 |
Why?
|
| Age Factors | 10 | 2017 | 1860 | 0.430 |
Why?
|
| Neoplasm Staging | 16 | 2020 | 799 | 0.430 |
Why?
|
| Dehydroepiandrosterone Sulfate | 5 | 2013 | 9 | 0.430 |
Why?
|
| Focus Groups | 4 | 2016 | 247 | 0.430 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 154 | 0.430 |
Why?
|
| Glutathione Transferase | 3 | 2009 | 166 | 0.420 |
Why?
|
| Serine Endopeptidases | 1 | 2012 | 50 | 0.420 |
Why?
|
| Thymine DNA Glycosylase | 1 | 2012 | 2 | 0.420 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2012 | 74 | 0.420 |
Why?
|
| fas Receptor | 1 | 2012 | 54 | 0.420 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 38 | 0.410 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 61 | 0.410 |
Why?
|
| Translations | 1 | 2012 | 12 | 0.410 |
Why?
|
| Motor Activity | 3 | 2016 | 621 | 0.410 |
Why?
|
| Parents | 1 | 2014 | 309 | 0.400 |
Why?
|
| Lysophospholipids | 1 | 2013 | 209 | 0.400 |
Why?
|
| Ships | 1 | 2011 | 5 | 0.400 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 53 | 0.400 |
Why?
|
| Population Surveillance | 8 | 2016 | 285 | 0.400 |
Why?
|
| Solar System | 1 | 2011 | 2 | 0.400 |
Why?
|
| Weight Gain | 2 | 2016 | 135 | 0.400 |
Why?
|
| Logistic Models | 16 | 2019 | 1419 | 0.390 |
Why?
|
| Automobiles | 1 | 2011 | 26 | 0.390 |
Why?
|
| Group Processes | 1 | 2011 | 42 | 0.390 |
Why?
|
| Housing | 1 | 2011 | 38 | 0.390 |
Why?
|
| Tobacco Use Cessation | 1 | 2011 | 44 | 0.390 |
Why?
|
| Sphingosine | 1 | 2013 | 315 | 0.380 |
Why?
|
| Nutrition Surveys | 4 | 2020 | 204 | 0.380 |
Why?
|
| Sex Factors | 7 | 2014 | 1265 | 0.370 |
Why?
|
| Dietary Supplements | 6 | 2017 | 331 | 0.370 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 152 | 0.360 |
Why?
|
| Vitamin A | 6 | 2015 | 111 | 0.360 |
Why?
|
| Sphingolipids | 1 | 2013 | 337 | 0.360 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 240 | 0.350 |
Why?
|
| Medical History Taking | 2 | 2020 | 94 | 0.350 |
Why?
|
| Survival Analysis | 8 | 2017 | 714 | 0.340 |
Why?
|
| Sex Distribution | 7 | 2016 | 272 | 0.340 |
Why?
|
| Ceramides | 1 | 2013 | 578 | 0.340 |
Why?
|
| Brassicaceae | 1 | 2009 | 2 | 0.330 |
Why?
|
| Vitamin E | 7 | 2006 | 55 | 0.330 |
Why?
|
| Alcoholism | 1 | 2017 | 1109 | 0.330 |
Why?
|
| Walking | 1 | 2011 | 241 | 0.330 |
Why?
|
| Health Behavior | 4 | 2021 | 458 | 0.320 |
Why?
|
| Dopamine beta-Hydroxylase | 1 | 2008 | 24 | 0.320 |
Why?
|
| Monoamine Oxidase | 1 | 2008 | 26 | 0.320 |
Why?
|
| Restaurants | 1 | 2008 | 29 | 0.310 |
Why?
|
| Skin | 1 | 2011 | 451 | 0.310 |
Why?
|
| Arsenic | 1 | 2008 | 46 | 0.310 |
Why?
|
| Particulate Matter | 1 | 2008 | 41 | 0.310 |
Why?
|
| Water Supply | 1 | 2008 | 54 | 0.310 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2008 | 31 | 0.310 |
Why?
|
| Public Policy | 1 | 2008 | 71 | 0.300 |
Why?
|
| Respiratory Tract Diseases | 2 | 2008 | 43 | 0.300 |
Why?
|
| Premenopause | 5 | 2017 | 57 | 0.300 |
Why?
|
| Nutritional Status | 1 | 2008 | 112 | 0.300 |
Why?
|
| Rectal Neoplasms | 1 | 2007 | 75 | 0.290 |
Why?
|
| Recreation | 2 | 2017 | 19 | 0.290 |
Why?
|
| Health Education | 4 | 2017 | 279 | 0.290 |
Why?
|
| Comorbidity | 8 | 2019 | 1425 | 0.290 |
Why?
|
| Mutation | 1 | 2012 | 1213 | 0.290 |
Why?
|
| Quality of Life | 4 | 2018 | 1515 | 0.290 |
Why?
|
| Food Preservation | 1 | 2006 | 9 | 0.280 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2005 | 44 | 0.280 |
Why?
|
| Bronchial Neoplasms | 1 | 2006 | 12 | 0.280 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 264 | 0.280 |
Why?
|
| Prostatic Neoplasms | 6 | 2015 | 778 | 0.280 |
Why?
|
| Awareness | 1 | 2007 | 81 | 0.280 |
Why?
|
| Patient Selection | 1 | 2010 | 592 | 0.280 |
Why?
|
| Confidence Intervals | 6 | 2016 | 242 | 0.270 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 98 | 0.270 |
Why?
|
| Preventive Medicine | 1 | 2006 | 48 | 0.270 |
Why?
|
| Alcohol Drinking | 3 | 2009 | 805 | 0.270 |
Why?
|
| Community Networks | 1 | 2006 | 96 | 0.260 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2013 | 52 | 0.260 |
Why?
|
| Age Distribution | 6 | 2010 | 319 | 0.260 |
Why?
|
| Risk | 7 | 2016 | 563 | 0.260 |
Why?
|
| Schools, Medical | 1 | 2007 | 157 | 0.260 |
Why?
|
| Causality | 4 | 2011 | 81 | 0.260 |
Why?
|
| Selenium | 6 | 2017 | 36 | 0.260 |
Why?
|
| Educational Status | 5 | 2009 | 273 | 0.250 |
Why?
|
| Ganglionic Stimulants | 1 | 2005 | 15 | 0.250 |
Why?
|
| Exercise | 3 | 2021 | 658 | 0.250 |
Why?
|
| Inflammation | 3 | 2019 | 1030 | 0.250 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 91 | 0.240 |
Why?
|
| Health Services Accessibility | 3 | 2006 | 581 | 0.240 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2004 | 12 | 0.240 |
Why?
|
| Mass Screening | 5 | 2009 | 838 | 0.240 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2004 | 11 | 0.240 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 1046 | 0.240 |
Why?
|
| Regression Analysis | 5 | 2011 | 737 | 0.230 |
Why?
|
| Pregnant Women | 2 | 2021 | 50 | 0.230 |
Why?
|
| Registries | 6 | 2022 | 730 | 0.230 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 378 | 0.230 |
Why?
|
| Statistics, Nonparametric | 5 | 2011 | 306 | 0.220 |
Why?
|
| Absenteeism | 1 | 2003 | 27 | 0.220 |
Why?
|
| Product Labeling | 2 | 2013 | 43 | 0.220 |
Why?
|
| SEER Program | 4 | 2016 | 150 | 0.220 |
Why?
|
| Time Factors | 10 | 2016 | 4655 | 0.210 |
Why?
|
| Genetic Variation | 2 | 2022 | 220 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 332 | 0.210 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2022 | 5 | 0.210 |
Why?
|
| Vitamins | 4 | 2007 | 134 | 0.210 |
Why?
|
| Sunlight | 2 | 2014 | 59 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 1465 | 0.200 |
Why?
|
| Gene Frequency | 3 | 2012 | 207 | 0.200 |
Why?
|
| DNA, Mitochondrial | 3 | 2006 | 84 | 0.190 |
Why?
|
| Folic Acid | 2 | 2006 | 121 | 0.190 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 261 | 0.190 |
Why?
|
| Survival Rate | 7 | 2018 | 1055 | 0.190 |
Why?
|
| Parity | 3 | 2018 | 71 | 0.180 |
Why?
|
| Vitamin B 12 | 1 | 2000 | 21 | 0.180 |
Why?
|
| Homocysteine | 1 | 2000 | 26 | 0.180 |
Why?
|
| Pregnancy | 5 | 2021 | 2334 | 0.180 |
Why?
|
| Chronic Disease | 5 | 2010 | 1329 | 0.180 |
Why?
|
| Emigration and Immigration | 1 | 2000 | 33 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 1 | 1999 | 12 | 0.180 |
Why?
|
| Urban Population | 2 | 2006 | 254 | 0.180 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 37 | 0.170 |
Why?
|
| Occupational Exposure | 2 | 2013 | 122 | 0.170 |
Why?
|
| Referral and Consultation | 3 | 2021 | 383 | 0.170 |
Why?
|
| Glucuronosyltransferase | 1 | 2019 | 38 | 0.170 |
Why?
|
| Life Style | 2 | 2021 | 338 | 0.170 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 10 | 0.170 |
Why?
|
| Social Environment | 2 | 2019 | 182 | 0.170 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 68 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 30 | 0.160 |
Why?
|
| Trust | 1 | 2019 | 75 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 536 | 0.160 |
Why?
|
| Genital Diseases, Female | 1 | 2018 | 23 | 0.160 |
Why?
|
| Psychology | 1 | 2018 | 36 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 278 | 0.160 |
Why?
|
| Cotinine | 2 | 2015 | 40 | 0.160 |
Why?
|
| Postmenopause | 3 | 2011 | 92 | 0.160 |
Why?
|
| Child | 10 | 2018 | 6401 | 0.160 |
Why?
|
| Racism | 1 | 2019 | 59 | 0.160 |
Why?
|
| Public Health | 2 | 2017 | 201 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 32 | 0.160 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2017 | 38 | 0.160 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 7 | 0.150 |
Why?
|
| Tumor Virus Infections | 3 | 2004 | 32 | 0.150 |
Why?
|
| Sterilization, Tubal | 1 | 2017 | 5 | 0.150 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 235 | 0.150 |
Why?
|
| Immunization Programs | 1 | 2017 | 25 | 0.150 |
Why?
|
| Cancer Survivors | 1 | 2020 | 145 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 1745 | 0.150 |
Why?
|
| Ovulation | 1 | 2017 | 10 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2017 | 64 | 0.150 |
Why?
|
| Obesity | 3 | 2016 | 1074 | 0.140 |
Why?
|
| Dairy Products | 1 | 2016 | 13 | 0.140 |
Why?
|
| Minerals | 2 | 2007 | 43 | 0.140 |
Why?
|
| Reproductive History | 1 | 2016 | 8 | 0.140 |
Why?
|
| Calcium, Dietary | 1 | 2016 | 35 | 0.140 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 28 | 0.140 |
Why?
|
| Perception | 1 | 2017 | 189 | 0.140 |
Why?
|
| Powders | 1 | 2016 | 32 | 0.140 |
Why?
|
| Lymphocytes | 2 | 2015 | 228 | 0.140 |
Why?
|
| Neoplasm Grading | 4 | 2019 | 110 | 0.140 |
Why?
|
| Mouth Neoplasms | 3 | 2010 | 206 | 0.140 |
Why?
|
| Saliva | 3 | 2006 | 142 | 0.140 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2016 | 3 | 0.140 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 9 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2019 | 448 | 0.140 |
Why?
|
| Glycemic Load | 1 | 2015 | 1 | 0.140 |
Why?
|
| Hypertension | 2 | 2020 | 1533 | 0.140 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 18 | 0.140 |
Why?
|
| Sarcoma, Kaposi | 2 | 2006 | 24 | 0.130 |
Why?
|
| alpha-Tocopherol | 1 | 2015 | 5 | 0.130 |
Why?
|
| Global Health | 3 | 2009 | 135 | 0.130 |
Why?
|
| Micronutrients | 4 | 2003 | 31 | 0.130 |
Why?
|
| Dietary Carbohydrates | 1 | 2015 | 27 | 0.130 |
Why?
|
| Glycemic Index | 1 | 2015 | 28 | 0.130 |
Why?
|
| Protective Agents | 1 | 2016 | 36 | 0.130 |
Why?
|
| Primary Prevention | 2 | 2007 | 115 | 0.130 |
Why?
|
| Qualitative Research | 2 | 2016 | 369 | 0.130 |
Why?
|
| Research Design | 2 | 2010 | 729 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 69 | 0.130 |
Why?
|
| Antioxidants | 4 | 2003 | 304 | 0.130 |
Why?
|
| False Negative Reactions | 1 | 2015 | 63 | 0.130 |
Why?
|
| Herpesvirus 8, Human | 2 | 2005 | 24 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2077 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2017 | 403 | 0.130 |
Why?
|
| Health Policy | 2 | 2014 | 221 | 0.130 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 700 | 0.120 |
Why?
|
| Analgesics | 1 | 2016 | 118 | 0.120 |
Why?
|
| Breast Feeding | 1 | 2016 | 159 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 204 | 0.120 |
Why?
|
| Vaccination | 1 | 2016 | 182 | 0.120 |
Why?
|
| Rhinitis | 2 | 2010 | 383 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2015 | 156 | 0.120 |
Why?
|
| Hotlines | 1 | 2014 | 51 | 0.120 |
Why?
|
| Sinusitis | 2 | 2010 | 432 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1994 | 92 | 0.120 |
Why?
|
| Mouth Diseases | 2 | 2004 | 38 | 0.120 |
Why?
|
| Medical Record Linkage | 2 | 2012 | 42 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 475 | 0.110 |
Why?
|
| Financing, Government | 1 | 2013 | 16 | 0.110 |
Why?
|
| Health Priorities | 1 | 2013 | 23 | 0.110 |
Why?
|
| Resource Allocation | 1 | 2013 | 35 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2011 | 84 | 0.110 |
Why?
|
| Biomarkers | 6 | 2015 | 1593 | 0.110 |
Why?
|
| State Government | 1 | 2013 | 34 | 0.110 |
Why?
|
| Organizational Objectives | 1 | 2013 | 70 | 0.110 |
Why?
|
| Community-Based Participatory Research | 2 | 2016 | 133 | 0.110 |
Why?
|
| Probability | 3 | 2018 | 244 | 0.110 |
Why?
|
| Air Pollution | 1 | 2013 | 54 | 0.110 |
Why?
|
| Leukocyte Elastase | 1 | 2012 | 19 | 0.110 |
Why?
|
| Retrospective Studies | 9 | 2015 | 7268 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 136 | 0.100 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 373 | 0.100 |
Why?
|
| Uterine Neoplasms | 2 | 2018 | 99 | 0.100 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 438 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2017 | 659 | 0.100 |
Why?
|
| Sunbathing | 1 | 2011 | 1 | 0.100 |
Why?
|
| Iceland | 1 | 2011 | 2 | 0.100 |
Why?
|
| Postoperative Complications | 3 | 2015 | 1615 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 502 | 0.100 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 2 | 2001 | 13 | 0.090 |
Why?
|
| DNA, Viral | 3 | 2005 | 114 | 0.090 |
Why?
|
| Dentists | 1 | 2010 | 18 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 492 | 0.090 |
Why?
|
| HIV Infections | 3 | 2006 | 775 | 0.090 |
Why?
|
| Mannose-Binding Lectin | 1 | 2009 | 3 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 1054 | 0.090 |
Why?
|
| Asthma | 1 | 1994 | 345 | 0.090 |
Why?
|
| Reference Values | 2 | 2010 | 579 | 0.090 |
Why?
|
| Sunburn | 1 | 2009 | 6 | 0.090 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 16 | 0.090 |
Why?
|
| Sunscreening Agents | 1 | 2009 | 7 | 0.090 |
Why?
|
| Protective Clothing | 1 | 2009 | 12 | 0.090 |
Why?
|
| Antibodies, Viral | 2 | 2003 | 110 | 0.090 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2009 | 29 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2016 | 1341 | 0.080 |
Why?
|
| Cyclooxygenase 1 | 2 | 2006 | 29 | 0.080 |
Why?
|
| Electron Transport Complex IV | 2 | 2006 | 33 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2021 | 159 | 0.080 |
Why?
|
| Phenotype | 1 | 2012 | 946 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2009 | 18 | 0.080 |
Why?
|
| Ascorbic Acid | 2 | 2000 | 45 | 0.080 |
Why?
|
| Residence Characteristics | 2 | 2009 | 252 | 0.080 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2001 | 147 | 0.080 |
Why?
|
| Fertility | 1 | 2008 | 60 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2004 | 753 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2008 | 1753 | 0.080 |
Why?
|
| Women's Health | 3 | 2017 | 148 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2009 | 219 | 0.080 |
Why?
|
| Herpesviridae Infections | 2 | 2005 | 23 | 0.080 |
Why?
|
| Population Groups | 1 | 2008 | 16 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2008 | 112 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 2 | 2006 | 160 | 0.080 |
Why?
|
| Geography | 1 | 2008 | 80 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 951 | 0.080 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 307 | 0.080 |
Why?
|
| Infant | 1 | 2014 | 2891 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 281 | 0.080 |
Why?
|
| Baltimore | 5 | 2006 | 34 | 0.080 |
Why?
|
| Fruit | 1 | 2008 | 86 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 2 | 2005 | 53 | 0.080 |
Why?
|
| Asbestos | 1 | 2007 | 7 | 0.080 |
Why?
|
| Radon | 1 | 2007 | 8 | 0.080 |
Why?
|
| Sociobiology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Epidemiologic Research Design | 1 | 2007 | 5 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 424 | 0.070 |
Why?
|
| Censuses | 1 | 2007 | 6 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 33 | 0.070 |
Why?
|
| Environment Design | 1 | 2007 | 40 | 0.070 |
Why?
|
| Urban Health | 1 | 2007 | 49 | 0.070 |
Why?
|
| Demography | 3 | 2016 | 279 | 0.070 |
Why?
|
| Marital Status | 1 | 2007 | 65 | 0.070 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2007 | 32 | 0.070 |
Why?
|
| Air Pollutants | 1 | 2007 | 75 | 0.070 |
Why?
|
| Culture | 1 | 2007 | 75 | 0.070 |
Why?
|
| Physicians | 1 | 2010 | 324 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 180 | 0.070 |
Why?
|
| China | 1 | 2006 | 138 | 0.070 |
Why?
|
| Trace Elements | 1 | 2006 | 23 | 0.070 |
Why?
|
| G2 Phase | 1 | 2005 | 26 | 0.070 |
Why?
|
| Risk-Taking | 1 | 2007 | 210 | 0.060 |
Why?
|
| HIV-1 | 1 | 2006 | 177 | 0.060 |
Why?
|
| Bias | 1 | 2006 | 148 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2010 | 657 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2004 | 56 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2005 | 111 | 0.060 |
Why?
|
| Arachidonate Lipoxygenases | 1 | 2004 | 3 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2006 | 224 | 0.060 |
Why?
|
| Cell Division | 1 | 2005 | 541 | 0.060 |
Why?
|
| Family | 1 | 2006 | 293 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 1195 | 0.060 |
Why?
|
| Cytokines | 1 | 2009 | 866 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 73 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 929 | 0.060 |
Why?
|
| Mortality | 1 | 2005 | 162 | 0.060 |
Why?
|
| Reference Standards | 1 | 2004 | 115 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 94 | 0.060 |
Why?
|
| Gender Identity | 1 | 2004 | 47 | 0.060 |
Why?
|
| Models, Biological | 1 | 2008 | 981 | 0.060 |
Why?
|
| Cisplatin | 1 | 2005 | 192 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2013 | 17 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2005 | 411 | 0.060 |
Why?
|
| Women | 1 | 2003 | 40 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2003 | 59 | 0.060 |
Why?
|
| gamma-Tocopherol | 1 | 2003 | 1 | 0.060 |
Why?
|
| Astrocytoma | 1 | 2003 | 30 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 308 | 0.060 |
Why?
|
| Bleomycin | 1 | 2003 | 67 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2004 | 179 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 77 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 86 | 0.050 |
Why?
|
| Interviews as Topic | 2 | 2016 | 392 | 0.050 |
Why?
|
| Tocopherols | 1 | 2002 | 7 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 772 | 0.050 |
Why?
|
| Recurrence | 1 | 2004 | 948 | 0.050 |
Why?
|
| Schools | 1 | 2003 | 156 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2000 | 179 | 0.050 |
Why?
|
| Italy | 3 | 2006 | 36 | 0.050 |
Why?
|
| BRCA2 Protein | 2 | 1998 | 18 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2002 | 117 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 938 | 0.050 |
Why?
|
| Retinoids | 1 | 2002 | 122 | 0.050 |
Why?
|
| Environmental Pollutants | 2 | 2001 | 180 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1174 | 0.050 |
Why?
|
| Nomograms | 1 | 2020 | 19 | 0.050 |
Why?
|
| El Salvador | 1 | 2000 | 8 | 0.050 |
Why?
|
| Mammography | 2 | 2000 | 310 | 0.050 |
Why?
|
| District of Columbia | 1 | 2000 | 23 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2020 | 49 | 0.040 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 5 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 90 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 18 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 756 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 142 | 0.040 |
Why?
|
| England | 1 | 2019 | 64 | 0.040 |
Why?
|
| DDT | 1 | 1999 | 19 | 0.040 |
Why?
|
| Social Values | 1 | 2019 | 34 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 371 | 0.040 |
Why?
|
| Anticarcinogenic Agents | 2 | 2016 | 52 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 117 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 132 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 103 | 0.040 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 1998 | 6 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2019 | 51 | 0.040 |
Why?
|
| Ovarian Cysts | 1 | 2018 | 9 | 0.040 |
Why?
|
| Leiomyoma | 1 | 2018 | 28 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 1998 | 47 | 0.040 |
Why?
|
| Sleep | 1 | 2021 | 263 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2018 | 39 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 266 | 0.040 |
Why?
|
| Endometriosis | 1 | 2018 | 56 | 0.040 |
Why?
|
| Australia | 1 | 2019 | 235 | 0.040 |
Why?
|
| Hospice Care | 1 | 2018 | 29 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2018 | 45 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 213 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 20 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 239 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 349 | 0.040 |
Why?
|
| Menopause | 4 | 2000 | 47 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 307 | 0.040 |
Why?
|
| Education, Medical | 1 | 1999 | 147 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 215 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7028 | 0.040 |
Why?
|
| Research Personnel | 1 | 2016 | 83 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 131 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Hormones | 1 | 1995 | 42 | 0.030 |
Why?
|
| Gamma Rays | 2 | 2006 | 64 | 0.030 |
Why?
|
| Craving | 1 | 2017 | 200 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 39 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 53 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 57 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 271 | 0.030 |
Why?
|
| Linear Models | 2 | 2012 | 521 | 0.030 |
Why?
|
| Steroids | 1 | 1995 | 84 | 0.030 |
Why?
|
| Prostate | 1 | 2015 | 116 | 0.030 |
Why?
|
| Cognition | 1 | 1999 | 512 | 0.030 |
Why?
|
| Health Personnel | 1 | 2017 | 286 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Curriculum | 1 | 1999 | 575 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 100 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 2 | 2004 | 41 | 0.030 |
Why?
|
| United States Public Health Service | 1 | 2014 | 4 | 0.030 |
Why?
|
| Androstenedione | 1 | 1994 | 7 | 0.030 |
Why?
|
| Epidemiology | 1 | 2014 | 14 | 0.030 |
Why?
|
| Anniversaries and Special Events | 1 | 2014 | 12 | 0.030 |
Why?
|
| Depression | 1 | 2021 | 942 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 694 | 0.030 |
Why?
|
| Policy Making | 1 | 2014 | 51 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 239 | 0.030 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 292 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2014 | 73 | 0.030 |
Why?
|
| Freezing | 1 | 1993 | 29 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2014 | 199 | 0.030 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 14 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2009 | 369 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 248 | 0.030 |
Why?
|
| Product Packaging | 1 | 2012 | 17 | 0.030 |
Why?
|
| Progesterone | 1 | 1994 | 115 | 0.030 |
Why?
|
| Estrogens | 1 | 1994 | 173 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 64 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2004 | 186 | 0.030 |
Why?
|
| Health Literacy | 1 | 2012 | 62 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 780 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2018 | 824 | 0.020 |
Why?
|
| beta Carotene | 2 | 2006 | 16 | 0.020 |
Why?
|
| Diagnosis, Oral | 1 | 2010 | 14 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1992 | 253 | 0.020 |
Why?
|
| Nasal Obstruction | 1 | 2009 | 34 | 0.020 |
Why?
|
| United Kingdom | 1 | 2009 | 152 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1992 | 450 | 0.020 |
Why?
|
| Sociology, Medical | 1 | 2007 | 2 | 0.020 |
Why?
|
| Models, Econometric | 1 | 2007 | 26 | 0.020 |
Why?
|
| Systems Integration | 1 | 2007 | 30 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 2007 | 32 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2007 | 93 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 25 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 98 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 125 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2005 | 35 | 0.020 |
Why?
|
| DNA Primers | 1 | 2006 | 302 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2006 | 163 | 0.020 |
Why?
|
| Viral Load | 1 | 2005 | 127 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 3 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 124 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2005 | 129 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2004 | 91 | 0.020 |
Why?
|
| Actins | 1 | 2006 | 249 | 0.020 |
Why?
|
| Tonsillar Neoplasms | 1 | 2004 | 7 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 191 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2005 | 79 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 710 | 0.010 |
Why?
|
| Haplotypes | 1 | 2004 | 174 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 420 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 2004 | 10 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 621 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2003 | 20 | 0.010 |
Why?
|
| Dental Care | 1 | 2003 | 34 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2004 | 65 | 0.010 |
Why?
|
| JC Virus | 1 | 2003 | 5 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 2003 | 24 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 386 | 0.010 |
Why?
|
| BK Virus | 1 | 2003 | 17 | 0.010 |
Why?
|
| Mutagens | 1 | 2003 | 18 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 1037 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2003 | 239 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 705 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 176 | 0.010 |
Why?
|
| Needs Assessment | 1 | 2003 | 186 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 929 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 467 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2004 | 617 | 0.010 |
Why?
|
| Blood Banks | 1 | 1999 | 6 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 2324 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 554 | 0.010 |
Why?
|
| Brazil | 1 | 1999 | 48 | 0.010 |
Why?
|
| Menarche | 1 | 1998 | 18 | 0.010 |
Why?
|
| DNA Probes | 1 | 1998 | 57 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1998 | 25 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 95 | 0.010 |
Why?
|
| Free Radicals | 1 | 1997 | 65 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 1997 | 64 | 0.010 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1996 | 8 | 0.010 |
Why?
|
| Carcinogens, Environmental | 1 | 1996 | 16 | 0.010 |
Why?
|
| BRCA1 Protein | 1 | 1996 | 30 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 61 | 0.010 |
Why?
|
| Tamoxifen | 1 | 1996 | 62 | 0.010 |
Why?
|
| Gonadotropins | 1 | 1995 | 4 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1997 | 567 | 0.010 |
Why?
|
| Androgens | 1 | 1995 | 41 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 235 | 0.010 |
Why?
|
| Health Promotion | 1 | 1999 | 407 | 0.010 |
Why?
|
| Cholesterol | 1 | 1996 | 331 | 0.010 |
Why?
|
| Prolactin | 1 | 1994 | 61 | 0.010 |
Why?
|
| Drug Stability | 1 | 1993 | 71 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 164 | 0.010 |
Why?
|
| Bed Rest | 1 | 1992 | 17 | 0.010 |
Why?
|
| Cardiac Catheterization | 1 | 1992 | 419 | 0.010 |
Why?
|